Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | XB002 |
Synonyms | |
Therapy Description |
XB002 is an antibody-drug conjugate (ADC) comprising a tissue factor (TF)-targeted monoclonal antibody linked to auristatin, which potentially induces cell cycle arrest and apoptosis in tumor cells expressing TF (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
XB002 | XB-002|XB 002 | XB002 is an antibody-drug conjugate (ADC) comprising a tissue factor (TF)-targeted monoclonal antibody linked to auristatin, which potentially induces cell cycle arrest and apoptosis in tumor cells expressing TF (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04925284 | Phase I | XB002 Nivolumab + XB002 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | BEL | AUS | 1 |